Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors
Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.
Aim(s): The utility of chromogranin B (CgB), belonging to the same granin family as CgA, was examined as a biomarker for pNET.
Materials and methods: Serum CgB were determined by radioimmunoassay and serum CgA levels by ELISA in patients with pNET (n = 91) and other pancreatic conditions, and in healthy people (n = 104), to assess the relationships with clinical features.
Conference: 14th Annual ENETSConcerence (2017)
To read the full abstract, please log into your ENETS Member account.